17.08.2022 13:41:56

Quest Diagnostics Adds HCV Screening To Its New Obstetrics Test Panel

(RTTNews) - Quest Diagnostics (DGX) announced the launch of a new obstetrics laboratory test panel designed to enable physicians to screen all eligible pregnant people for hepatitis C with other laboratory tests typically ordered during early pregnancy. The company noted that the new test panel follows a Quest Diagnostics Health Trends study with the CDC that revealed less than half of pregnant people are screened for hepatitis C as recommended under guidelines.

Damian "Pat" Alagia, Senior Medical Director, Women's Health, Quest Diagnostics, said: "By adding HCV screening to our obstetrics panel, physicians will be more likely to deliver guideline-based care that reduces HCV infection during pregnancy and fosters a positive outcome for the patient and their newborn."

For More Such Health News, visit rttnews.com.

Analysen zu Quest Diagnostics Inc.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Quest Diagnostics Inc. 145,30 0,10% Quest Diagnostics Inc.